FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereafter FRONTEO) is an objective using AI for depression and manic depression with Keio University (location: Minato-ku, Tokyo). We have signed a memorandum of change regarding the joint research agreement regarding the development of technology for evaluating the severity of illness, its utilization in clinical situations, and the development of technology for social implementation.

 

　Since 2015, FRONTEO has been conducting joint research with Keio University School of Medicine to develop a "conversational dementia diagnosis support AI program" that screens for cognitive dysfunction using AI, and in April 2020. We have a research contract.We are planning to conclude a memorandum of change related to this contract and develop depression and manic-depressive illness for clinical development and social implementation as well as dementia.

 

　According to the Ministry of Health, Labor and Welfare "Patient Survey", the number of outpatients with mood (emotional) disorders in Japan increased from 2002 to 2017 million in the 15 years from 68.5 to 124.6, about 1.8 times.¹⁾, About 100 out of 6 people are said to experience depression in their lifetime²⁾..In addition, the number of people with Alzheimer's disease increased from 7 to 51.3, about 7.3 times.¹⁾, Estimated to reach 2025 million in 730 (about 5 in 1 elderly people)³⁾..Countermeasures against these diseases can be said to be one of the important social issues in Japan.

 

 

　FRONTEO completed the case registration of clinical trials in December 2021 in the development of the "Conversational Dementia Diagnosis Support AI Program" based on this joint research, and is currently in the process of regulatory approval.We will apply the knowledge accumulated through this research and development to depression and manic-depressive illness, aiming for early commercialization and market penetration of AI-based diagnostic support programs in the medical field.

 

　The impact of this matter alone on the business results for the current fiscal year is minor, but we will promptly notify you if there are any matters to be disclosed.

 

1) Ministry of Health, Labor and Welfare: Patient Survey, Summary of Results, https://www.mhlw.go.jp/toukei/list/10-20-kekka_gaiyou.html
2) Ministry of Health, Labor and Welfare: Let's start by knowing everyone's mental health, depression, https://www.mhlw.go.jp/kokoro/know/disease_depressive.html
3) Ministry of Health, Labor and Welfare: Comprehensive promotion of dementia measures, https://www.mhlw.go.jp/content/12300000/000519620.pdf

 

■ About FRONTEO　URL:https://www.fronteo.com/
FRONTEO uses the in-house developed AI engine "KIBIT", "Concept Encoder", and "Looca Cross" specializing in natural language processing to extract meaningful and important information from a huge amount of text data, and is a company. It is a data analysis company that supports the business of. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support corporate international litigation. Has been developed.Based on the AI ​​technology cultivated in this business, we will expand the business field to the life science field, business intelligence field, and economic security from 8, and by using AI to "turn text data into knowledge", We contribute to solving various corporate issues such as drug discovery support, dementia diagnosis support, financial, personnel, and sales support. Listed on TSE Mothers (currently TSE Growth) on June 2014, 2007. Obtained a first-class medical device manufacturing and sales business license in January 6 (permit number: 26B2021X1), and notified the managed medical device sales business in September of the same year (notification number: 13 Minato Misei Equipment No. 1).The capital is 10350 thousand yen (as of March 9, 3).

■ About conversational dementia diagnosis support AI program　URL:https://lifescience.fronteo.com/aidevice/dementia/
The "Conversational Dementia Diagnosis Support Program" (AI medical device) uses FRONTEO's original natural language analysis AI "Concept Encoder" to enable cognitive dysfunction from daily conversation between a doctor and a patient for about 5 to 10 minutes. It is a system that can screen. FRONTEO believes that this system can contribute to the progress of digital medical care such as telemedicine and the efficiency and standardization of medical care, in addition to measures against dementia, which is an important issue in Japan, which has entered a super-aging society. I am. We started clinical trials in April 2021 and are currently working toward early manufacturing and marketing approval and early launch.Patent registration number: Patent No. 4

■ About Concept Encoder　URL:https://lifescience.fronteo.com/technology/conceptencoder/
"Concept Encoder (Trademark: concept encoder, reading: Concept Encoder)" is a natural language analysis AI (artificial intelligence) developed by FRONTEO specially in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. Concept Encoder can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals, and various test values ​​that have been accumulated in the life science field.Patent registration number: Patent No. 6346367.

* FRONTEO, KIBIT, and concept encoder are registered trademarks of FRONTEO in Japan.